Redefining New Boundaries in Delivering Patient Care

As we reflect on the passing year 2024 – year of Dragon, we are thrilled to share our success story! magAssist has stayed true to its mission of saving the lives of cardiac patients. This is the highest recognition and a testament to the multidisciplinary teamwork, global partners' commitment, and the company’s dedication to delivering the best heart failure technologies for patient care. 

Achievements that make a Difference:

• MoyoAssist®: With a novel state-of-the-art magnetic suspension extracorporeal ventricular assist device (Extra VAD®) receiving NMPA approval, we set the record high with the system's first clinical application at the renowned Wuhan Union Hospital in China, the center of excellence in the treatment of heart failure patients. This global recognition is a testament to our shared mission and the impact we are making on a worldwide scale. 

• NyokAssist®: Globally recognized as the artificial heart technology to receive both the FDA’s Breakthrough Device designation and NMPA’s Innovative Medical Device status, the NyokAssist® is leading clinical trials, with over 100 patient enrollments and firm, encouraging results. Our caregiver and patient outcomes are an encouraging demonstration of our long-standing commitment to providing exceptional to patients and caregivers. 

• Design Excellence: Our state-of-the-art MoyoAssist® Extra VAD® has been honored with the prestigious 2024 iF Design Award, which underscores our commitment to innovative, patient-centric design. Founded in 1953, iF Design is one of the world's most important and prestigious design awards. Every year, several thousand designers, architects, and companies worldwide participate in having their designs evaluated by independent design experts. This award validates our design approach and reinforces our belief that patient-centric design is crucial in improving patient outcomes.

• Growth and Trust: With substantial backing from multiple investors, we continue to expand our impact and push the boundaries of innovation in cardiovascular care. The 2024 mark the magAssist’s outstanding performance and consistent excellence in delivering top-notch solutions close to patients and healthcare systems across the Nation. This growth and trust in our company's future is a testament to our shared vision and commitment to excellence. 

• Intellectual Property Excellence: Recognized as the “Outstanding Intellectual Property Management Team of 2024,” we remain committed to safeguarding and fostering the growth of our groundbreaking technologies and demonstrating industry-leading results. 

A Year of Recognition: From being named to the 2024 VENTURE50’s TOP50 and Healthcare TOP50 lists to winning the “Most Capital-Attractive Company” award at the Suzhou International Science and Innovation Conference, magAssist has earned significant recognition for its contributions to advancing medical technology. These accolades are a testament to our shared dedication and the credibility of our work in the medical technology field.

Expanding Our Academic Influence: We have expanded our academic footprint, showcasing state-of-the-art MoyoAssist® technology at the 50th European Society for Artificial Organs (ESAO) Annual Meeting held on Sept 08-11, Aachen, Germany. The NyokAssist®’s presentation of early clinical at the prestigious 36th Transcatheter Cardiovascular Therapeutics (TCT) Annual Meeting attracts thousands of attendees worldwide to feature major medical research breakthroughs and discuss the latest evidence-based research. Through our Extra VAD® training programs and active participation in 26 academic events, we have shaped the future of cardiovascular care while fostering global collaboration and knowledge exchange.

The International Society for Mechanical Circulatory Support (ISMCS) in China? Yes, unanimously approved by the Society’s Board, the magAssist has been awarded a unique opportunity to host this important scientific event for the first time in China. The event would bring the world's top heart failure technology and medical device elite to Suzhou, China, in 2026. 

A Vision for 2025: As we enter 2025 – the year of Snake, we remain committed to our major mission, saving lives by providing state-of-the-art, cutting-edge cardiovascular care solutions to patients and hospitals worldwide. In the coming year, we aim to further reinforce our impact by consistently delivering excellence through research and innovation. We are deeply grateful for the unwavering support of our team, partners, and investors and are excited to continue building a brighter, healthier future together.

Here’s to a new year of possibilities, purpose, and progress.